FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204808788> ?p ?o ?g. }

• W3204808788 endingPage "669" @default.
• W3204808788 startingPage "658" @default.
• W3204808788 abstract "Importance: Owing to its anti-inflammatory properties and antiviral in vitro effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cannabidiol (CBD) has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19). Objective: To investigate the safety and efficacy of CBD for treating patients with mild to moderate COVID-19. Design: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted between July 7 and October 16, 2020, in two sites in Brazil. Setting: Patients were recruited in an emergency room. Participants: Block randomized patients (1:1 allocation ratio-by a researcher not directly involved in data collection) with mild and moderate COVID-19 living in Ribeirão Preto, Brazil, seeking medical consultation, and those who voluntarily agreed to participate in the study. Interventions: Patients received 300 mg of CBD or placebo added to standard symptomatic care during 14 days. Main Outcome and Measure: The primary outcome was reduction or prevention of the deterioration in clinical status from mild/moderate to severe/critical measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms. Primary study outcome was assessed on days 14, 21, and 28 after enrollment. Results: A total of 321 patients were recruited and assessed for eligibility, and 105 were randomly allocated either in CBD (n=49) or in placebo (n=42) group. Ninety-one participants were included in the analysis of efficacy. There were no baseline between-group differences regarding disease severity (χ2=0.025, p=0.988) and median time to symptom resolution (12 days [95% confidence interval, CI, 6.5-17.5] in the CBD group, 9 days [95% CI, 4.8-13.2] in the placebo group [χ2=1.6, p=0.205 by log-rank test]). By day 28, 83.3% in the CBD group and 90.2% in the placebo group had resolved symptoms. There were no between-group differences on secondary measures. CBD was well tolerated, producing mostly mild and transient side effects (e.g., somnolence, fatigue, changes in appetite, lethargy, nausea, diarrhea, and fever), with no significant differences between CBD and placebo treatment groups. Conclusions and Relevance: Daily administration of 300 mg CBD for 14 days failed to alter the clinical evolution of COVID-19. Further trials should explore the therapeutic effect of CBD in patients with severe COVID-19, possibly trying higher doses than the used in our study. Trial Registration: ClinicalTrials.gov identifier NCT04467918 (date of registration: July 13, 2020)." @default.
• W3204808788 created "2021-10-11" @default.
• W3204808788 creator A5004107018 @default.
• W3204808788 creator A5005554732 @default.
• W3204808788 creator A5009745666 @default.
• W3204808788 creator A5012849944 @default.
• W3204808788 creator A5014651246 @default.
• W3204808788 creator A5018604668 @default.
• W3204808788 creator A5020538697 @default.
• W3204808788 creator A5021220130 @default.
• W3204808788 creator A5026159894 @default.
• W3204808788 creator A5026333926 @default.
• W3204808788 creator A5027294107 @default.
• W3204808788 creator A5028260877 @default.
• W3204808788 creator A5038216604 @default.
• W3204808788 creator A5042762358 @default.
• W3204808788 creator A5052649289 @default.
• W3204808788 creator A5053727929 @default.
• W3204808788 creator A5054036019 @default.
• W3204808788 creator A5054108139 @default.
• W3204808788 creator A5057308016 @default.
• W3204808788 creator A5058075680 @default.
• W3204808788 creator A5058457121 @default.
• W3204808788 creator A5062714997 @default.
• W3204808788 creator A5065631892 @default.
• W3204808788 creator A5066511141 @default.
• W3204808788 creator A5067784336 @default.
• W3204808788 creator A5071171320 @default.
• W3204808788 creator A5071272686 @default.
• W3204808788 creator A5075426951 @default.
• W3204808788 creator A5077848496 @default.
• W3204808788 creator A5081732044 @default.
• W3204808788 creator A5087307007 @default.
• W3204808788 date "2022-10-01" @default.
• W3204808788 modified "2023-10-18" @default.
• W3204808788 title "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" @default.
• W3204808788 cites W1497893548 @default.
• W3204808788 cites W1964906165 @default.
• W3204808788 cites W1989916516 @default.
• W3204808788 cites W2058844148 @default.
• W3204808788 cites W2095963786 @default.
• W3204808788 cites W2100987960 @default.
• W3204808788 cites W2136557533 @default.
• W3204808788 cites W2144853102 @default.
• W3204808788 cites W2340873232 @default.
• W3204808788 cites W2890537675 @default.
• W3204808788 cites W2890803317 @default.
• W3204808788 cites W2901647481 @default.
• W3204808788 cites W2981783294 @default.
• W3204808788 cites W2982171504 @default.
• W3204808788 cites W2998864681 @default.
• W3204808788 cites W3016535995 @default.
• W3204808788 cites W3017061263 @default.
• W3204808788 cites W3018276152 @default.
• W3204808788 cites W3021393314 @default.
• W3204808788 cites W3022592783 @default.
• W3204808788 cites W3034007980 @default.
• W3204808788 cites W3041559918 @default.
• W3204808788 cites W3052947531 @default.
• W3204808788 cites W3084842516 @default.
• W3204808788 cites W3092755033 @default.
• W3204808788 cites W3112965324 @default.
• W3204808788 cites W3124894221 @default.
• W3204808788 cites W3128642997 @default.
• W3204808788 cites W3132366281 @default.
• W3204808788 cites W3155814285 @default.
• W3204808788 doi "https://doi.org/10.1089/can.2021.0093" @default.
• W3204808788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34619044" @default.
• W3204808788 hasPublicationYear "2022" @default.
• W3204808788 type Work @default.
• W3204808788 sameAs 3204808788 @default.
• W3204808788 citedByCount "21" @default.
• W3204808788 countsByYear W32048087882022 @default.
• W3204808788 countsByYear W32048087882023 @default.
• W3204808788 crossrefType "journal-article" @default.
• W3204808788 hasAuthorship W3204808788A5004107018 @default.
• W3204808788 hasAuthorship W3204808788A5005554732 @default.
• W3204808788 hasAuthorship W3204808788A5009745666 @default.
• W3204808788 hasAuthorship W3204808788A5012849944 @default.
• W3204808788 hasAuthorship W3204808788A5014651246 @default.
• W3204808788 hasAuthorship W3204808788A5018604668 @default.
• W3204808788 hasAuthorship W3204808788A5020538697 @default.
• W3204808788 hasAuthorship W3204808788A5021220130 @default.
• W3204808788 hasAuthorship W3204808788A5026159894 @default.
• W3204808788 hasAuthorship W3204808788A5026333926 @default.
• W3204808788 hasAuthorship W3204808788A5027294107 @default.
• W3204808788 hasAuthorship W3204808788A5028260877 @default.
• W3204808788 hasAuthorship W3204808788A5038216604 @default.
• W3204808788 hasAuthorship W3204808788A5042762358 @default.
• W3204808788 hasAuthorship W3204808788A5052649289 @default.
• W3204808788 hasAuthorship W3204808788A5053727929 @default.
• W3204808788 hasAuthorship W3204808788A5054036019 @default.
• W3204808788 hasAuthorship W3204808788A5054108139 @default.
• W3204808788 hasAuthorship W3204808788A5057308016 @default.
• W3204808788 hasAuthorship W3204808788A5058075680 @default.
• W3204808788 hasAuthorship W3204808788A5058457121 @default.
• W3204808788 hasAuthorship W3204808788A5062714997 @default.
• W3204808788 hasAuthorship W3204808788A5065631892 @default.

• next